Increased levels of NETosis biomarkers in high-grade serous ovarian cancer patients' biofluids: Potential role in disease diagnosis and management.
NETosis
biomarkers
calprotectin
cfDNA
high-grade serous ovarian cancer
peritoneal fluid
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
11
2022
accepted:
27
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
High-grade serous ovarian cancer (HGSOC) is the second most frequent gynecological malignancy but the most lethal, partially due to the spread of the disease through the peritoneal cavity. Recent evidence has shown that, apart from their role in immune defense through phagocytosis and degranulation, neutrophils are able to participate in cancer progression through the release of neutrophil extracellular traps (NETs) in a process called NETosis. NETs are composed of DNA, histones, calprotectin, myeloperoxidase (MPO) and elastase and the NETosis process has been proposed as a pre-requisite for the establishment of omental metastases in early stages of HGSOC. Nevertheless, its role in advanced stages remains to be elucidated. Therefore, our principal aim is to characterize a NETosis biomarker profile in biofluids from patients with advanced HGSOC and control women. Specifically, five biomarkers of NETosis (cell-free DNA (cfDNA), nucleosomes, citrullinated histone 3 (citH3), calprotectin and MPO) were quantified in plasma and peritoneal fluid (PF) samples from patients (n=45) and control women (n=40). Our results showed that HGSOC patients presented a higher concentration of cfDNA, citH3 and calprotectin in plasma and of all five NETosis biomarkers in PF than control women. Moreover, these biomarkers showed a strong ability to differentiate the two clinical groups. Interestingly, neoadjuvant treatment (NT) seemed to reduce NETosis biomarkers mainly systemically (plasma) compared to the tumor environment (PF). In conclusion, NETosis biomarkers are present in the tumor environment of patients with advanced HGSOC, which might contribute to the progression of the disease. Besides, plasma cfDNA and calprotectin could represent minimally invasive surrogate biomarkers for HGSOC. Finally, NT modifies NETosis biomarkers levels mainly at the systemic level.
Identifiants
pubmed: 36817483
doi: 10.3389/fimmu.2023.1111344
pmc: PMC9936152
doi:
Substances chimiques
Histones
0
Biomarkers
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111344Informations de copyright
Copyright © 2023 Tomás-Pérez, Oto, Aghababyan, Herranz, Cuadros-Lozano, González-Cantó, Mc Cormack, Arrés, Castaño, Cana, Martínez-Fernández, Santonja, Ramírez, Herreros-Pomares, Cañete-Mota, Llueca, Marí-Alexandre, Medina and Gilabert-Estellés.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Biochem Biophys. 2018 Feb 15;640:47-52
pubmed: 29336940
J Clin Oncol. 2015 Sep 10;33(26):2841-7
pubmed: 26240233
Mol Oral Microbiol. 2019 Apr;34(2):27-38
pubmed: 30632295
J Exp Med. 2019 Jan 7;216(1):176-194
pubmed: 30567719
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Eur J Surg Oncol. 2021 Jan;47(1):101-107
pubmed: 31128948
Clin Chim Acta. 2016 Aug 1;459:89-93
pubmed: 27259468
Crit Rev Oncol Hematol. 2019 Apr;136:64-69
pubmed: 30878130
Front Immunol. 2020 Sep 16;11:1749
pubmed: 33042107
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Curr Treat Options Oncol. 2015 Apr;16(4):14
pubmed: 25796375
Semin Immunol. 2021 Oct;57:101595
pubmed: 35125298
Front Immunol. 2022 Aug 19;13:937565
pubmed: 36059520
World J Clin Oncol. 2018 Dec 20;9(8):167-171
pubmed: 30622924
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8
pubmed: 20439745
Am Fam Physician. 2016 Jun 1;93(11):937-44
pubmed: 27281838
Thromb Res. 2016 Mar;139:56-64
pubmed: 26916297
Tumour Biol. 2015 Sep;36(10):7549-56
pubmed: 25916207
Nat Med. 2021 Jul;27(7):1250-1261
pubmed: 34239134
Acta Obstet Gynecol Scand. 2007;86(3):260-5
pubmed: 17364298
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
J Exp Med. 2022 Jun 6;219(6):
pubmed: 35522219
Am J Gastroenterol. 2003 Oct;98(10):2299-305
pubmed: 14572583
Oncotarget. 2017 Jul 11;8(28):46414-46424
pubmed: 28423365
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
Int J Mol Sci. 2020 Aug 06;21(16):
pubmed: 32781781
Inflamm Res. 2018 Oct;67(10):801-812
pubmed: 30083975
Cancer Immunol Immunother. 2009 Jan;58(1):15-23
pubmed: 18414853
Nat Rev Cancer. 2020 Sep;20(9):485-503
pubmed: 32694624
Tissue Cell. 2017 Feb;49(1):95-105
pubmed: 27890350
Crit Rev Clin Lab Sci. 2019 Aug;56(5):307-320
pubmed: 31088326
PLoS One. 2016 Jun 02;11(6):e0155495
pubmed: 27253331
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545233
Gynecol Oncol. 2021 Jan;160(1):32-39
pubmed: 33196436
Int J Mol Sci. 2020 Jan 28;21(3):
pubmed: 32012923
Br J Cancer. 2020 Jul;123(1):9-16
pubmed: 32382112
Biomedicines. 2022 Feb 12;10(2):
pubmed: 35203640
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13076-81
pubmed: 22826226
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Cancer Lett. 2011 Apr 28;303(2):73-83
pubmed: 21353386
Cancer Biol Ther. 2019;20(8):1057-1067
pubmed: 30990132
J Ovarian Res. 2019 Feb 11;12(1):16
pubmed: 30744662
J Cell Biol. 2009 Jan 26;184(2):205-13
pubmed: 19153223
Thromb Haemost. 2018 Jan;118(1):6-27
pubmed: 29304522
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Chin Clin Oncol. 2018 Dec;7(6):56
pubmed: 30509078
Haematologica. 2021 Jun 01;106(6):1636-1646
pubmed: 32586906
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Front Oncol. 2021 Aug 12;11:714357
pubmed: 34476216
J Thromb Haemost. 2015 May;13(5):732-42
pubmed: 25418346
Immunity. 2020 Apr 14;52(4):700-715.e6
pubmed: 32294409
Int J Mol Sci. 2019 Oct 25;20(21):
pubmed: 31731537
PLoS One. 2015 Dec 30;10(12):e0145754
pubmed: 26717006
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1777-83
pubmed: 22652600
J Thromb Haemost. 2018 Mar;16(3):508-518
pubmed: 29325226
Am J Obstet Gynecol. 2008 Apr;198(4):418.e1-7
pubmed: 18241816
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817625
Ann Clin Biochem. 2015 Nov;52(Pt 6):660-4
pubmed: 25732128